Literature DB >> 7824870

Pharmacology of ursodeoxycholic acid, an enterohepatic drug.

A F Hofmann1.   

Abstract

The pharmacokinetics, metabolism, as well as the pharmacodynamic actions of ursodeoxycholic acid are reviewed and related to its physicochemical properties. Ursodeoxycholic acid is absorbed incompletely because of its low aqueous solubility. After absorption, it is conjugated with glycine or taurine and circulates with the endogenous bile acids. At usual doses (8-10 mg/kg/day), the pool of ursodeoxycholyl conjugates constitutes 30-60% of circulating bile acids. Ursodeoxycholic acid is metabolized by intestinal bacteriae to lithocholic acid which does not accumulate in the circulating bile acids because of efficient hepatic sulfation. Administration of ursodeoxycholic acid causes decreased cholesterol absorption, increased bile acid biosynthesis, and decreased biliary cholesterol secretion. Ursodeoxycholic acid is a choleretic agent, as all bile acids, but differs from other dihydroxy-bile acids in being non-cytotoxic because it has less affinity for membranes, and when present at micellar concentrations does not solubilize membranes. Chronic administration of ursodeoxycholic acid appears to increase canalicular transport.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7824870     DOI: 10.3109/00365529409103618

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  40 in total

Review 1.  Primary sclerosing cholangitis: updates in diagnosis and therapy.

Authors:  Piero Portincasa; Michele Vacca; Antonio Moschetta; Michele Petruzzelli; Giuseppe Palasciano; Karel J van Erpecum; Gerard P van Berge-Henegouwen
Journal:  World J Gastroenterol       Date:  2005-01-07       Impact factor: 5.742

2.  Ileal absorption of bile acids in patients with chronic cholestasis: SeHCAT test results and effect of ursodeoxycholic acid (UDCA).

Authors:  O Chazouillères; P Marteau; M Haniche; R Jian; R Poupon
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

Review 3.  Use of ursodeoxycholic acid in patients with liver disease.

Authors:  Paul Angulo
Journal:  Curr Gastroenterol Rep       Date:  2002-02

Review 4.  Ursodeoxycholic acid treatment of vanishing bile duct syndromes.

Authors:  Thomas Pusl; Ulrich Beuers
Journal:  World J Gastroenterol       Date:  2006-06-14       Impact factor: 5.742

5.  No significant effect of the SLCO1B1 polymorphism on the pharmacokinetics of ursodeoxycholic acid.

Authors:  Xiaoqiang Xiang; Juha Vakkilainen; Janne T Backman; Pertti J Neuvonen; Mikko Niemi
Journal:  Eur J Clin Pharmacol       Date:  2011-06-08       Impact factor: 2.953

6.  Paediatric cholestatic liver disease: Diagnosis, assessment of disease progression and mechanisms of fibrogenesis.

Authors:  Tamara N Pereira; Meagan J Walsh; Peter J Lewindon; Grant A Ramm
Journal:  World J Gastrointest Pathophysiol       Date:  2010-06-15

Review 7.  Ursodeoxycholic acid for primary biliary cirrhosis.

Authors:  Jelena S Rudic; Goran Poropat; Miodrag N Krstic; Goran Bjelakovic; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

8.  Ursodeoxycholic acid ameliorates experimental ileitis counteracting intestinal barrier dysfunction and oxidative stress.

Authors:  Carlos Felipe Bernardes-Silva; Adérson O M C Damião; Aytan M Sipahi; Francisco R M Laurindo; Kiyoshi Iriya; Fabio P Lopasso; Carlos A Buchpiguel; Maria Laura L Lordello; Carmem L O Agostinho; Antonio A Laudanna
Journal:  Dig Dis Sci       Date:  2004-10       Impact factor: 3.199

9.  Serum bile acid profiling reflects enterohepatic detoxification state and intestinal barrier function in inflammatory bowel disease.

Authors:  Carsten Gnewuch; Gerhard Liebisch; Thomas Langmann; Benjamin Dieplinger; Thomas Mueller; Meinhard Haltmayer; Hans Dieplinger; Alexandra Zahn; Wolfgang Stremmel; Gerhard Rogler; Gerd Schmitz
Journal:  World J Gastroenterol       Date:  2009-07-07       Impact factor: 5.742

10.  Bile acids in treatment of ocular disease.

Authors:  Jeffrey H Boatright; John M Nickerson; Anisha G Moring; Machelle T Pardue
Journal:  J Ocul Biol Dis Infor       Date:  2009-08-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.